Glucosylceramide and lysophosphatidylcholines as potential blood biomarkers for drug-induced hepatic phospholipidosis

Toxicological Sciences

Volumn 141, Issue 2, 2014, Pages 377-386

  Saito, Kosuke ^a   Maekawa, Keiko ^a   Ishikawa, Masaki ^a   Senoo, Yuya ^a   Urata, Masayo ^a   Murayama, Mayumi ^a   Nakatsu, Noriyuki ^b   Yamada, Hiroshi ^b   Saito, Yoshiro ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

Biomarker; Ketoconazole; Lipidomics; Phospholipidosis; Tricyclic antidepressant

Indexed keywords

AMITRIPTYLINE; BIOLOGICAL MARKER; CLOMIPRAMINE; GLUCOSYLCERAMIDE; IMIPRAMINE; KETOCONAZOLE; LYSOPHOSPHATIDYLCHOLINE; PHOSPHOLIPID; SPHINGOLIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; HEPATIC PHOSPHOLIPIDOSIS; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPIDOMICS; LIPIDOSIS; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER DISEASE; MALE; MASS SPECTROMETRY; NONHUMAN; RAT; SCREENING TEST; TREATMENT DURATION; ANIMAL; BILE DUCT; BLOOD; CHEMICALLY INDUCED; DISCRIMINANT ANALYSIS; DISEASE MODEL; DRUG-INDUCED LIVER INJURY; LEAST SQUARE ANALYSIS; LIVER; LYSOSOMAL STORAGE DISEASES; METABOLISM; METABOLOMICS; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROCEDURES;

AMITRIPTYLINE; ANIMALS; BILE DUCTS; BIOMARKERS; CHROMATOGRAPHY, LIQUID; CLOMIPRAMINE; DISCRIMINANT ANALYSIS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; GLUCOSYLCERAMIDES; HEPATOCYTES; IMIPRAMINE; LEAST-SQUARES ANALYSIS; LIVER; LYSOPHOSPHATIDYLCHOLINES; LYSOSOMAL STORAGE DISEASES; MALE; MASS SPECTROMETRY; METABOLOMICS; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RATS;

EID: 84911467749     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu132     Document Type: Article

References (37)

1. Abe, A., Hiraoka, M. and Shayman, J.A. (2007). A role for lysosomal phospholipase A2 in drug induced phospholipidosis. Drug Metab. Lett. 1, 49-53.
2. Anderson, N. and Borlak, J. (2006). Drug-induced phospholipidosis. FEBS Lett. 580, 5533-5540.
3. Baronas, E.T., Lee, J.W., Alden, C. and Hsieh, F.Y. (2007). Biomarkers to monitor drug-induced phospholipidosis. Toxicol. Appl. Pharmacol. 218, 72-78.
4. Bu, Q., Huang, Y., Yan, G., Cen, X. and Zhao, Y.L. (2012). Metabolomics: A revolution for novel cancer marker identification. Comb. Chem. High Throughput Screen. 15, 266-275.
5. Carroll, M. (1981). Genetic heterogeneity of membrane-bound beta-glucosidase in Gaucher's disease. J. Inherit. Metab. Dis. 4, 11-13.
6. Cheng, J., Ma, X., Krausz, K.W., Idle, J.R. and Gonzales, F.J. (2009). Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab. Dispos. 37, 1611-1621.
7. Delaney, J., Neville, W.A., Swain, A., Miles, A., Leonard, M.S. and Waterfield, C.J. (2004). Phenylacetylglycine, a putative biomarker of phospholipidosis: Its origins and relevance to phospholipid accumulation using amiodarone treated rats as a model. Biomarkers 9, 271-290.
8. Faul, F., Erdfelder, E., Lang, A.G. and Buchner, A. (2007). G*3 Power 3: A flexible statistical power analysis program for the social, behavioral, and biological sciences. Behav. Res. Methods 39, 175-191.
9. Floegel, A., Stefan, N., Yu, Z., Mühlenbruch, K., Drogan, D., Joost, H.G., Fritsche, A., Häring, H.U., Hrabe de Angelis, M., Peters, A., et al., (2013). Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 62, 639-648.
10. Gowda, G.A., Zhang, S., Gu, H., Asiago, V., Shanaiah, N. and Raftery,D. (2008).Metabolomics-based methods for early disease diagnostics. Expert Rev. Mol. Diagn. 8, 617-633.
11. Halliwell, W.H. (1997). Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 25, 53-60.
12. Hiraoka, M., Abe, A., Lu, Y., Yang, K., Han, X., Gross, R.W. and Shayman, J.A. (2006). Lysosomal phospholipase A2 and phospholipidosis. Mol. Cell Biol. 26, 6139-6148.
13. Hirode, M., Ono, A., Miyagishima, T., Nagao, T., Ohno, Y. and Urushidani, T. (2008). Gene expression profiling in rat liver treated with compounds inducing phospholipidosis. Toxicol. Appl. Pharmacol. 229, 290-299.
14. Ishikawa, M., Maekawa, K., Saito, K., Senoo, Y., Urata, M., Murayama, M., Tajima, Y., Kumagai, Y. and Saito, Y. (2014). Plasma and serum lipidomics of healthy white adults shows characteristic profiles by subjects' gender and age. PLoS One 9, e91806.
15. James, S.P., Stromeyer, F.W., Chang, C. and Barranger, J.A. (1981). LIver abnormalities in patients with Gaucher's disease. Gastroenterology 80, 126-133.
16. Jungermann, K. (1986). Functional heterogeneity of periportal and perivenous hepatocytes. Enzyme 35, 161-180.
17. Kern, E.L. (1966). Separation of gluco- and galactocerebrosides by means of borate thin-layer chromatography. J. Lipid Res. 7, 449-452.
18. Kodavanti, U.P. and Mehendale, H.M. (1990). Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol. Rev. 42, 327-354.
19. Lewis, J.H., Ranard, R.C., Caruso, A., Jackson, L.K., Mullick, F., Ishak, K.G., Seeff, L.B. and Zimmerman, H.J. (1989). Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients. Hepatology 9, 679-685.
20. Lüllmann, H., Lüllmann-Rauch, R. and Wassermann, O. (1975). Drug-induced phospholipidoses. II. Tissue distribution of the amphiphilic drug chlorphentermine. CRC Crit. Rev. Toxicol. 4, 185-218.
21. Lüllmann, H., Lüllmann-Rauch, R. and Wassermann, O. (1978). Lipidosis induced by amphiphilic cationic drugs. Biochem. Pharmacol. 27, 1103-1108.
22. Ma, J., Yu, J., Su, X., Zhu, C., Yang, X., Sun, H., Chen, D., Wang, Y., Cao, H. and Lu, J. (2014). UPLC-MS-based serum metabonomics for identifying acute liver injury biomarkers in Chinese miniature pigs. Toxicol. Lett. 225, 358-366.
23. Maekawa, K., Hirayama, A., Iwata, Y., Tajima, Y., Nishimaki-Mogami, T., Sugawara, S., Ueno, N., Abe, H., Ishikawa, M., Murayama, M., et al., (2013) Global metabolomic analysis of heart tissue in a hamster model for dilated cardiomyopathy. J. Mol. Cel. Cardiol. 59, 76-85.
24. Mortuza, G.B., Neville, W.A., Delaney, J., Waterfield, C.J. and Camilleri, P. (2003). Characterisation of a potential biomarker of phospholipidosis from amiodarone-treated rats. Biochem. Biophys. Acta. 1631, 136-146.
25. Poucell, S., Ireton, J., Valencia-Mayoral, P., Downar, E., Larratt, L., Patterson, J., Blendis, L. and Phillips, M.J. (1984). Amiodaroneassociated phospholipidosis and fibrosis of the liver. Light, immunohistochemical, and electron microscopic studies. Gastroenterology 86, 926-936.
26. Reasor, M.J. (1989). A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. Toxicol. Appl. Pharmacol. 97, 47-56.
27. Reasor, M.J. and Kacew, S. (2001). Drug-induced phospholipidosis: Are there functional consequences? Exp. Biol. Med. 226, 825-830.
28. Rigas, B., Rosenfeld, L.E., Barwick, K.W., Enriquez, R., Helzberg, J., Batsford, W.P., Josephson, M.E. and Riely, C.A. (1986). Amiodarone hepatotoxicity. A clinicopathologic study of five patients. Ann. Intern. Med. 104, 348-351.
29. Sekas, G., Patton, G.M., Lincoln, E.C. and Robins, S.J. (1985). Origin of plasma lysophosphatidylcholine: Evidence for direct hepatic secretion in the rat. J. Lab. Clin. Med. 105, 190-194.
30. Spratlin, J.L., Serkova, N.J. and Eckhardt, S.G. (2009). Clinical applications of metabolomics in oncology: A review. Clin. Cancer Res. 15, 431-440.
31. Tajima, Y., Ishikawa, M., Maekawa, K., Murayama, M., Senoo, Y., Nishimaki-Mogami, T., Nakanishi, H., Ikeda, K., Arita, M., Taguchi, R., et al., (2013). Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis. 12, 68.
32. Thompson, K.L., Haskins, K., Rosenzweig, B.A., Stewart, S., Zhang, J., Peters, D., Knapton, A., Rouse, R., Mans, D. and Colatsky, T. (2012). Comparison of the diagnostic accuracy of di-22:6-bis(monoacylglycerol)phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat. Int. J. Toxicol. 31, 14-24.
33. Tokoro, T., Gal, A.E., Gallo, L.L. and Brady, R.O. (1987). Studies of the pathogenesis of Gaucher's disease: Tissue distribution and biliary excretion of [14C]L-glucosylceramide in rats. J. Lipid Res. 28, 968-972.
34. Turpin, J.C.,Masson, M. and Baumann, N. (1991). Clinical aspects of Niemann-Pick type C disease in the adult. Dev. Neurosci. 13, 304-306.
35. Urushidani, T. and Nagao, T. (2005). Toxicogenomics: The Japanese initiative. In Handbook of Toxicogenomics-Strategies and Applications (J. Borlak Ed.) Wiley-VCH German pp. 623-631.
36. Yudate, H.T., Kai, T., Aoki, M., Minowa, Y., Yamada, T., Kimura, T., Ono, A., Yamada, H., Ohno, Y. and Urushidani, T. (2012). Identification of a novel set of biomarkers for evaluating phospholipidosis-inducing potential of compounds using rat livermicroarray data measured 24-h after single dose administration. Toxicology 295, 1-7.
37. Zhao, Z., Xiao, Y., Elson, P., Tan, H., Plummer, S.J., Berk, M., Aung, P.P., Lavery, I.C., Achkar, J.P., Li, L., et al. (2007). Plasma lysophosphatidylcholine levels: Potential biomarkers for colorectal cancer. J. Clin. Oncol. 25, 2696-2701.